特宝生物(688278.SH)：派格宾®增加适应症上市许可申请获得受理

智通财经03-15

智通财经APP讯，特宝生物(688278.SH)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，公司产品派格宾®(通用名：聚乙二醇干扰素α-2b注射液)联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请获得国家药监局受理。派格宾®是公司目前的核心产品，是公司自主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是治疗用生物制品国家1类新药，是我国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2419921190?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-15 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2419921190","market":"us","top_or_hot":-1,"title":"特宝生物(688278.SH)：派格宾®增加适应症上市许可申请获得受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，特宝生物(688278.SH)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，公司产品派格宾®(通用名：聚乙二醇干扰素α-2b注射液)联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请获得国家药监局受理。派格宾®是公司目前的核心产品，是公司自主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是治疗用生物制品国家1类新药，是我国...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1087169.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>特宝生物(688278.SH)：派格宾®增加适应症上市许可申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n特宝生物(688278.SH)：派格宾®增加适应症上市许可申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-15 19:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1087169.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，特宝生物(688278.SH)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，公司产品派格宾®(通用名：聚乙二醇干扰素α-2b注射液)联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请获得国家药监局受理。派格宾®是公司目前的核心产品，是公司自主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是治疗用生物制品国家1类新药，是我国...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1087169.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BMG7P926.USD","symbol_name":"Legg Mason ClearBridge - Global Infrastructure Income A Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1087169.html","article_id":"2419921190","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2419921190","pubTimestamp":1710500561,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，特宝生物 发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，公司产品派格宾联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请获得国家药监局受理。派格宾于2016年10月获批上市，获批适应症为适用于治疗成人慢性丙型肝炎，2017年9月获得慢性乙型肝炎适应症补充申请注册批件。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BMG7P926.USD":"Legg Mason ClearBridge - Global Infrastructure Income A Acc USD","IE00BMG7P819.SGD":"Legg Mason ClearBridge - Global Infrastructure Income A Mdis SGD-H Plus","BK4588":"碎股","PEG":"公务集团","BK4585":"ETF&股票定投概念","BK4208":"复合型公用事业","IE00BD4GTV84.USD":"LEGG MASON CLEARBRIDGEINFRASTRUCTURE VALUE \"A\" (USDHDG) ACC","IE00BMG7P694.USD":"Legg Mason ClearBridge - Global Infrastructure Income A Mdis USD Plus","IE00BMG7P587.USD":"LEGG MASON CLEARBRIDGE GLOBAL INFRASTRUCTURE INCOM \"A\" (USD) INC","IE00BD4GTW91.USD":"LEGG MASON CLEARBRIDGEINFRASTRUCTURE VALUE \"A\" (USDHDG) INC","IE00BD4GTT62.SGD":"Legg Mason ClearBridge Infrastructure Value A SGD-H (mdis) plus"},"translate_title":"Tebao Bio (688278. SH): The application for listing license for increasing indications in Pegbin ® was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEG":1},"content_text":"智通财经APP讯，特宝生物(688278.SH)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，公司产品派格宾®(通用名：聚乙二醇干扰素α-2b注射液)联合核苷(酸)类似物适用于临床治愈成人慢性乙型肝炎的增加适应症的上市许可申请获得国家药监局受理。派格宾®是公司目前的核心产品，是公司自主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是治疗用生物制品国家1类新药，是我国第一个国产上市的聚乙二醇(PEG)修饰干扰素品种。派格宾®于2016年10月获批上市，获批适应症为适用于治疗成人慢性丙型肝炎，2017年9月获得慢性乙型肝炎适应症补充申请注册批件。病毒性肝炎是我国十分突出的公共卫生问题，实现乙肝临床治愈对于降低患者肝硬化和肝癌发生率、提高健康水平具有重要意义。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2419921190"}